Hormone Drug

In 1999, the United States Food and Drug Administration (FDA) approved 0.75mg levonorgestrel tablets for use postcoitally as an emergency contraception (EC). In humans, physiologic studies have consistently found that levonorgestrel EC inhibits, delays, or modifies hormone profiles accompanying ovulation. The actual effectiveness of levonorgestrel emergency contraception has been estimated between 58% and 95% under different delays in administration.

Hormonal Treatment for Endometriosis

Gestrinone is a steroid with antiestrogen and antiprogesterone properties, a synthetic derivative of ethynyl-nor-testosterone that has been shown to reduce uterine volume. Therefore, gestrinone may be considered an option for the treatment of endometriosis.